A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Inclusion Criteria: * Have a clinical diagnosis of TED with or without proptosis and with any clinical activity score (CAS) (0 - 7) and in the opinion of the investigator may benefit from treatment * Must agree to use highly effective contraception method as specified in the protocol * Female TED participants must have a negative serum pregnancy test at screening * Not require immediate ophthalmological or orbital surgery in the study eye for any reason. Exclusion Criteria: * Must not have received prior treatment with another anti-IGF-1R therapy * Must not have used systemic corticosteroids, or selenium within 2 weeks prior to Day 1 * Must not have received rituximab, tocilizumab or other immunosuppressive agents within 8 weeks prior to Day 1 * Must not have received any other therapy for TED within 8 weeks prior to Day 1 * Must not have received an investigational agent for any condition within 8 weeks prior to the first dose of study medication * Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the Investigator would confound interpretation of the study results * Must not have had previous orbital irradiation or decompression surgery involving excision of fat for TED in the study eye's orbit * Must not have inflammatory bowel disease * Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor. * Female TED participants must not be pregnant or lactating.